1. Home
  2. IMMR vs LCTX Comparison

IMMR vs LCTX Comparison

Compare IMMR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMR
  • LCTX
  • Stock Information
  • Founded
  • IMMR 1993
  • LCTX 1990
  • Country
  • IMMR United States
  • LCTX United States
  • Employees
  • IMMR N/A
  • LCTX N/A
  • Industry
  • IMMR Computer peripheral equipment
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IMMR Technology
  • LCTX Health Care
  • Exchange
  • IMMR Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • IMMR 251.7M
  • LCTX 274.0M
  • IPO Year
  • IMMR 1999
  • LCTX N/A
  • Fundamental
  • Price
  • IMMR $7.17
  • LCTX $1.73
  • Analyst Decision
  • IMMR Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • IMMR 2
  • LCTX 4
  • Target Price
  • IMMR $12.25
  • LCTX $4.25
  • AVG Volume (30 Days)
  • IMMR 463.8K
  • LCTX 1.9M
  • Earning Date
  • IMMR 09-11-2025
  • LCTX 11-13-2025
  • Dividend Yield
  • IMMR 2.50%
  • LCTX N/A
  • EPS Growth
  • IMMR 57.07
  • LCTX N/A
  • EPS
  • IMMR 2.04
  • LCTX N/A
  • Revenue
  • IMMR $163,133,000.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • IMMR $988.71
  • LCTX N/A
  • Revenue Next Year
  • IMMR $109.72
  • LCTX $176.00
  • P/E Ratio
  • IMMR $3.48
  • LCTX N/A
  • Revenue Growth
  • IMMR 338.21
  • LCTX 76.43
  • 52 Week Low
  • IMMR $6.47
  • LCTX $0.37
  • 52 Week High
  • IMMR $10.72
  • LCTX $1.83
  • Technical
  • Relative Strength Index (RSI)
  • IMMR 46.14
  • LCTX 69.14
  • Support Level
  • IMMR $6.96
  • LCTX $1.64
  • Resistance Level
  • IMMR $7.48
  • LCTX $1.77
  • Average True Range (ATR)
  • IMMR 0.19
  • LCTX 0.11
  • MACD
  • IMMR -0.02
  • LCTX -0.00
  • Stochastic Oscillator
  • IMMR 18.62
  • LCTX 75.00

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: